Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AiXin Life International, Inc. (AIXN)
USD0.26
+0.00 (+0.00%)
CN OTC Healthcare Medical - Distribution
Address
Hongxing Intl. Business Bldg 2 610021
Chengdu, NW, CN
Chengdu, NW, CN
CEO
Quan Zhong Lin
Website
aixinjituan.com
IPO
2008-02-29
CIK 835662 ISIN US0096033099
Also trades on
Other OTC · AIXN (USD)
Other OTC · AIXND (USD)
Description
AiXin Life International, Inc. develops, manufactures, markets, and sells healthcare, nutritional products, and wellness supplements in the People's Republic of China. The company operates through four segments: Direct Sales, Pharmacy, Hotel, and Manufacture and Sale. It offers herbs, greens, and traditional Chinese remedies; and functional products, such as weight management tools, probiotics, and foods and drinks; and rhino king, colostrum powder derived from goat’s milk, tong li ke, gammaoling granules, amoxicillin capsules, loratadine tablets, and fuyang granules. The company also engages in hotel business. It provides products manufactured by the company and purchased from third parties, as well as marketing and distribution services to other manufacturers and suppliers of healthcare products. The company sells its products through company-owned offices open to clients, pharmacies, direct marketing, e-commerce, exhibition events, conferences, and person-to-person marketing. The company is based in Chengdu, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.26
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
96
Beta
-3.45
Float Shares
8.58M
Free Float %
34.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +24.03% | +57.64% | +91.62% | +95.12% | +90.48% | -37.25% | -80.00% | -97.71% | +1,119.05% | +457.25% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.26
Quality scores
Altman Z-Score
-13.60
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Distribution: +5.6%-61.1% Q4'25: -53.4% (vs Q4'24)
-
EPS growth Medical - Distribution: +4.9%+25.5% ★ Q4'25: +56.3% (vs Q4'24)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-117.2% Q4'25: -80.3% (vs Q4'24)
-
EBIT margin Medical - Distribution: +3.0%-135.9% Q4'25: -189.2% (vs Q4'24)
-
ROIC Medical - Distribution: +5.7%— Q4'25: +49.1% (vs Q4'24)
-
Share dilution Medical - Distribution: +0.0%+0.0% Q4'25: +0.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×-0.83× Q4'25: -2.02× (vs Q4'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-3.62M
OE per share TTM
-0.14
Owner's Yield
-45.28%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
67.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
4
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 52-2158952 | 43.82M | 96.50% | 43.82M | — | 43.82M | — | CO | Delaware | 2009-11-12 | ↗ |
| 2 | Quanzhong Lin | 29.07M | 58.14% | 29.07M | — | 29.07M | — | IN | or place of organization | 2023-02-13 | ↗ |
| 3 | L. Mathis | 8.63M | 19.00% | — | 8.63M | — | 8.63M | HC, IN | States | 2009-11-12 | ↗ |
| 4 | Yao-Te Wang | 3.77M | 7.54% | 3.77M | — | 3.77M | — | IN | or place of organization | 2023-02-13 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-06 | Zheng Xiaowen | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-01-24 | Lee Hsin-Liang Christopher | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-12 | Wang Yao-Te | Director | — | D | Common Stock | 0 | 0.00 | — | 15,074,695 | — | ↗ |
| 2017-12-12 | Lin Quanzhong | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 256,874,014 | — | ↗ |
| 2017-12-12 | Li Guolu | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-01-20 | MATHIS SCOTT L | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-01-20 | LAWRENCE PETER J.L. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-01-20 | Echevarria Maria I. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-01-20 | Algodon Wines & Luxury Development Group, Inc. | 10% Owner | S-Sale | D | Common Stock | 43,822,401 | 260,000.00 | 11.39T | 0 | — | ↗ |
| 2015-04-13 | Echevarria Maria I. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2009-11-09 | UNDERWOOD LAWRENCE M | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 200 | 900.00 | 180.0K | 692,210 | — | ↗ |
| 2009-11-09 | ROBBINS RONALD S | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2009-11-09 | MATHIS SCOTT L | Director / Officer | — | I | COMMON STOCK, $.00001 PAR VALUE | 0 | 0.00 | — | 8,630,275 | — | ↗ |
| 2009-11-09 | LAWRENCE PETER J.L. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2009-11-09 | Kanouff John Patrick | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 200 | 900.00 | 180.0K | 692,209 | — | ↗ |
| 2009-11-09 | HOLDERBAUM TIM F | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2009-11-09 | DIVERSIFIED PRIVATE EQUITY CORP | 10% Owner | — | D | COMMON STOCK, $.00001 PAR VALUE | 0 | 0.00 | — | 43,822,401 | — | ↗ |
| 2009-11-09 | BEALE JULIAN | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2008-06-04 | UNDERWOOD LAWRENCE M | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 14,762 | 0.00 | — | 692,410 | — | ↗ |
| 2008-06-04 | Kanouff John Patrick | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 14,762 | 0.00 | — | 692,409 | — | ↗ |
| 2008-06-02 | UNDERWOOD LAWRENCE M | Director / Officer / 10% Owner | J-Other | D | Common Stock | 1,775,089 | 0.00 | — | 710,036 | — | ↗ |
| 2008-06-02 | Kanouff John Patrick | Director / Officer / 10% Owner | J-Other | D | Common Stock | 1,775,090 | 0.00 | — | 710,036 | — | ↗ |
| 2008-02-25 | UNDERWOOD LAWRENCE M | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 25,000 | 0.00 | — | 2,485,125 | — | ↗ |
| 2008-02-25 | Kanouff John Patrick | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 25,000 | 0.00 | — | 2,485,126 | — | ↗ |
| 2007-11-27 | UNDERWOOD LAWRENCE M | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 750,000 | 0.01 | 7.5K | 2,510,125 | — | ↗ |
| 2007-11-27 | Kanouff John Patrick | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 750,000 | 0.01 | 7.5K | 2,510,126 | — | ↗ |
| 2007-06-18 | UNDERWOOD LAWRENCE M | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 500,000 | 0.01 | 5.0K | 1,760,125 | — | ↗ |
| 2007-06-18 | Kanouff John Patrick | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 500,000 | 0.01 | 5.0K | 1,760,126 | — | ↗ |
| 2007-04-24 | MARSIK ROBERT | — | J-Other | A | Common Stock | 0 | 0.00 | — | 216,000 | — | ↗ |
| 2007-04-23 | Higgins Thomas A | — | J-Other | A | Common Stock | 0 | 0.00 | — | 70,000 | — | ↗ |
| 2007-04-23 | BERGENFIELD ALLAN | — | J-Other | A | Common Stock | 0 | 0.00 | — | 14,000 | — | ↗ |
| 2007-03-21 | UNDERWOOD LAWRENCE M | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,285,125 | — | ↗ |
| 2007-03-21 | MARSIK ROBERT | Director / Officer / 10% Owner | D-Return | D | Common Stock | 345,917 | 0.00 | — | 216,000 | — | ↗ |
| 2007-03-21 | Kanouff John Patrick | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,285,126 | — | ↗ |
| 2007-03-21 | Higgins Thomas A | Director / 10% Owner | D-Return | D | Common Stock | 193,889 | 0.00 | — | 70,000 | — | ↗ |
| 2007-03-21 | BERGENFIELD ALLAN | Director / 10% Owner | D-Return | A | Common Stock | 30,445 | 0.00 | — | 14,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-16.9K
Shares Outstanding
25.00M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2021 | Quanzhong Lin, President | 24.0K | — | — | — | — | — | 24.0K | 0.00% | ↗ |
| 2 | 2021 | Guolu Li, Chief Financial Officer | 18.8K | — | — | — | — | — | 18.8K | 0.00% | ↗ |
| 3 | 2020 | Quanzhong Lin, President | 34.3K | — | — | — | — | — | 34.3K | 0.00% | ↗ |
| 4 | 2020 | Guolu Li, Chief Financial Officer | 18.0K | — | — | — | — | — | 18.0K | 0.00% | ↗ |
| 5 | 2019 | Quanzhong Lin, President | 34.3K | — | — | — | — | — | 34.3K | 0.00% | ↗ |
| 6 | 2019 | Guolu Li, Chief Financial Officer | 18.0K | — | — | — | — | — | 18.0K | 0.00% | ↗ |
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Quanzhong Lin | Secretary, President, Chief Executive Officer & Chairman | 41.0K | male |
| Xiaowen Zheng | Chief Financial Officer | 24.9K | male |
| Qiyu Jiang | Director & Secretary | — | male |
ESG Rating
ESG Score History FOOD DISTRIBUTION
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AIXN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
